Dynamic OGTT-derived C-peptide trajectories for metabolic heterogeneity and adverse pregnancy outcomes in gestational diabetes mellitus: a nested case‒control study.

IF 8.3 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Xinyue Wang, Zhangya He, Jing Ji, Simin Zhang, Jinglin Li, Jiahui Zhang, Wenlu Yu, Hexiang Yang, Zhen Han, Yang Mi, Xiaoqin Luo
{"title":"Dynamic OGTT-derived C-peptide trajectories for metabolic heterogeneity and adverse pregnancy outcomes in gestational diabetes mellitus: a nested case‒control study.","authors":"Xinyue Wang, Zhangya He, Jing Ji, Simin Zhang, Jinglin Li, Jiahui Zhang, Wenlu Yu, Hexiang Yang, Zhen Han, Yang Mi, Xiaoqin Luo","doi":"10.1186/s12916-025-04281-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Existing diagnostic criteria for gestational diabetes mellitus (GDM) rely solely on glucose thresholds, which are insufficient to capture metabolic heterogeneity. We aimed to evaluate the role of C-peptide measured during the oral glucose tolerance test (OGTT) in assisting the development of stratified treatment strategies and predicting the risk of adverse pregnancy outcomes.</p><p><strong>Methods: </strong>This nested case-control study conducted within the Xi'an Longitudinal Mother-Child Cohort included 1014 pregnant women with GDM and 1014 without GDM (non-GDM) who delivered singleton live-born infants between January 1, 2017, and December 31, 2018. C-peptide levels were measured at three intervals during the OGTT. Latent class trajectory modeling was used to identify distinct C-peptide trajectories, and logistic regression was used to assess their associations with adverse fetal and maternal outcomes.</p><p><strong>Results: </strong>Two principal C-peptide trajectories were identified in GDM despite similar glucose profiles. GDM Class 1 (771, 76.04%) presented a delayed 120-min C-peptide peak and poorer beta-cell secretion, whereas GDM Class 2 (243, 23.96%) presented a sharp 60-min peak followed by a decline and significantly increased insulin resistance, with greater risks of delivering large for gestational age (LGA) (adjusted odds ratio (aOR), 1.52; 95% confidence interval (CI), 1.07-2.15) and macrosomia (aOR, 1.83; 95% CI, 1.13-2.97). Surprisingly, 21.7% (220) of the non-GDM group had a high C-peptide response associated with elevated preeclampsia risk (aOR, 2.91; 95% CI, 1.25-6.74).</p><p><strong>Conclusions: </strong>Dynamic OGTT-derived C-peptide trajectories revealed clinically significant metabolic subgroups of GDM that were obscured by glucose-only diagnostics, with the predominantly insulin-resistant Class being at higher risk of fetal overgrowth.</p>","PeriodicalId":9188,"journal":{"name":"BMC Medicine","volume":"23 1","pages":"482"},"PeriodicalIF":8.3000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12366374/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12916-025-04281-x","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Existing diagnostic criteria for gestational diabetes mellitus (GDM) rely solely on glucose thresholds, which are insufficient to capture metabolic heterogeneity. We aimed to evaluate the role of C-peptide measured during the oral glucose tolerance test (OGTT) in assisting the development of stratified treatment strategies and predicting the risk of adverse pregnancy outcomes.

Methods: This nested case-control study conducted within the Xi'an Longitudinal Mother-Child Cohort included 1014 pregnant women with GDM and 1014 without GDM (non-GDM) who delivered singleton live-born infants between January 1, 2017, and December 31, 2018. C-peptide levels were measured at three intervals during the OGTT. Latent class trajectory modeling was used to identify distinct C-peptide trajectories, and logistic regression was used to assess their associations with adverse fetal and maternal outcomes.

Results: Two principal C-peptide trajectories were identified in GDM despite similar glucose profiles. GDM Class 1 (771, 76.04%) presented a delayed 120-min C-peptide peak and poorer beta-cell secretion, whereas GDM Class 2 (243, 23.96%) presented a sharp 60-min peak followed by a decline and significantly increased insulin resistance, with greater risks of delivering large for gestational age (LGA) (adjusted odds ratio (aOR), 1.52; 95% confidence interval (CI), 1.07-2.15) and macrosomia (aOR, 1.83; 95% CI, 1.13-2.97). Surprisingly, 21.7% (220) of the non-GDM group had a high C-peptide response associated with elevated preeclampsia risk (aOR, 2.91; 95% CI, 1.25-6.74).

Conclusions: Dynamic OGTT-derived C-peptide trajectories revealed clinically significant metabolic subgroups of GDM that were obscured by glucose-only diagnostics, with the predominantly insulin-resistant Class being at higher risk of fetal overgrowth.

Abstract Image

Abstract Image

妊娠期糖尿病代谢异质性和不良妊娠结局的动态ogtt衍生c肽轨迹:巢式病例对照研究
背景:现有的妊娠期糖尿病(GDM)诊断标准仅依赖于葡萄糖阈值,不足以捕捉代谢异质性。我们的目的是评估口服葡萄糖耐量试验(OGTT)中c肽的测量在协助分层治疗策略的制定和预测不良妊娠结局风险方面的作用。方法:本研究在西安纵向母婴队列中进行巢式病例对照研究,包括2017年1月1日至2018年12月31日期间分娩单胎活产婴儿的1014名GDM孕妇和1014名非GDM孕妇(非GDM)。在OGTT期间,每隔三个时间间隔测量c肽水平。使用潜在类别轨迹模型来识别不同的c肽轨迹,并使用逻辑回归来评估它们与胎儿和母体不良结局的关联。结果:两种主要的c肽轨迹在GDM中被确定,尽管葡萄糖谱相似。GDM 1类(771例,76.04%)患者的c肽峰延迟120分钟,β细胞分泌较差,而GDM 2类(243例,23.96%)患者的胰岛素抵抗在60分钟出现急剧高峰,随后下降并明显增加,分娩大胎龄(LGA)的风险较大(调整优势比(aOR), 1.52;95%置信区间(CI), 1.07-2.15)和巨大儿(aOR, 1.83; 95% CI, 1.13-2.97)。令人惊讶的是,21.7%(220)的非gdm组c肽反应高,与子痫前期风险升高相关(aOR, 2.91; 95% CI, 1.25-6.74)。结论:ogtt衍生的动态c肽轨迹揭示了GDM的临床重要代谢亚群,这些亚群被仅葡萄糖诊断所掩盖,主要是胰岛素抵抗类胎儿过度生长的风险更高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Medicine
BMC Medicine 医学-医学:内科
CiteScore
13.10
自引率
1.10%
发文量
435
审稿时长
4-8 weeks
期刊介绍: BMC Medicine is an open access, transparent peer-reviewed general medical journal. It is the flagship journal of the BMC series and publishes outstanding and influential research in various areas including clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities. In addition to research articles, the journal also publishes stimulating debates, reviews, unique forum articles, and concise tutorials. All articles published in BMC Medicine are included in various databases such as Biological Abstracts, BIOSIS, CAS, Citebase, Current contents, DOAJ, Embase, MEDLINE, PubMed, Science Citation Index Expanded, OAIster, SCImago, Scopus, SOCOLAR, and Zetoc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信